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Introduction
Fenofibrate (Figure 1a) has been a widely used drug in the treatment 
of dyslipidaemia [1]. It was originally launched in 1975 as a standard 
formulation and is now marketed in over 85 countries. Chemically, 
FBT is 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid,1-
methylethyl ester. Fenofibric acid (Figure 1b), the active metabolite of 
FBT, contributes to a reduction in total cholesterol, LDL cholesterol, 
apolipoprotien B, total triglycerides and triglyceride rich lipoprotein 
[2-7]. In addition, treatment with FBT also results in elevation of 
high-density lipoprotein (HDL) and apoproteins, viz., apoAI and 
apoAII. The effects of FA on lipid metabolism are mainly mediated 
through activation of the peroxisome proliferator-activated receptor 
α [8-10]. Following oral administration, FBT is well absorbed from 
the gastrointestinal tract, and is rapidly hydrolysed by the CYP3A4 
isozyme to FA [11-13]. The maximum plasma concentrations of FA 
are achieved within 4-5 h following oral dosing of FBT. No unchanged 
FBT is detected in plasma after oral dosing. The elimination half-life 
of FA is approximately 20 h [13,14]. FA is primarily conjugated with 
glucuronic acid and then excreted in urine [4,15]. No unexpected 
accumulation of FA has been reported during repeat administration 
[16,17]. After an oral administration of 100 or 200 mg of FBT, the 
typical peak concentration (Cmax) for FA is approximately 5-15 µg/
mL [18-23]. The use of non-statin drugs such as fibrates has been 
modest and many health care professionals avoid consideration of 
combination therapy due to an inordinate fear of toxicity. In order to 
study the pharmacokinetic parameters of FA in human studies, it is 
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Abstract
A high performance liquid chromatography method for the determination of fenofibric acid (FA), the active form 
of fenofibrate (FBT) in human plasma was developed and validated with 500 µL of human plasma using 4’-chloro-
5-fluro-2-hydroxybenzophenone (CFHB) as internal standard (IS). The assay procedure involved a simple one step 
liquid/liquid extraction of FA and IS from human plasma into ethyl acetate. The organic layer was separated and 
evaporated under a gentle stream of nitrogen at 40°C. The residue was reconstituted in the mobile phase and 
injected on a Symmetry ShieldRP18 (150×4.60 mm) 5 µm column. Separation of FA and IS was achieved with 
a mobile phase consisting of acetonitrile: 0.02 M phosphoric acid (50:50 v/v) at a flow rate of 1 mL/min. Nominal 
retention times of FA and IS were 6.1 and 9.1 ± 0.5 min, respectively. Absolute recovery of FA using a single step 
liquid/liquid method was 79.8%. A calibration curve was established for a range of concentrations 0.05 to 10.0 µg/mL 
with a regression coefficient (r2) of 0.9988. The lower limit of quantification (LLOQ) of FA was 0.05 µg/mL. The intra- 
and inter-day precision for the measurement of FA quality control samples (0.05, 0.12, 1.20 and 8.20 µg/mL), were in 
the range 4.6-16.9% and 4.4-17.2% relative standard deviations respectively. The accuracy in the measurement of 
QC samples for FA was in the range of 82.0-104.3% (intra-day) to 95.0-104.9% (inter-day). The method developed 
was successfully used to investigate the pharmacokinetics and bioequivalence between a micronized Lipidil-Micro™ 
capsule formulation and a nanonised fenofibrate Lipidil-EZ™ tablet formulation.
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Figure 1a: Fenofibrate
Figure 1b: Fenofibric Acid
Figure 1c: 4-chloro-5-fluro-2-
hydroxybenzophenone
Figure 1: Structures of (a) Fenofibrate (b) Fenofibric acid and (c) 4’-chloro-5-
fluro-2-hydroxybenzophenone.
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necessary to develop a method for its determination in plasma. There 
have been several papers on the determination of FBT or its metabolites 
in biological fluids using techniques such as HPLC, GC-MS and LC-
MS [7,17,21-26]. Our method uses a simple one step liquid/liquid 
extraction procedure and HPLC-UV detection with a novel internal 
standard of 4’-chloro-5-fluro-2-hydroxybenzophenone (CFHB), 
(Figure 1c). Compared to previously reported methods, the sensitivity 
and recovery using this method is superior, since the LLOQ is 0.05 µg/
mL and the calibrated range is 0.05 to 10.0 mg/L.
Lipidil is registered in Australia for the treatment of dyslipidaemia 
and hypercholesterolemia. The method developed was used to 
investigate the bioavailability of two different oral formulations of 
fenofibrate: the first formulation consisted of a 200 mg capsule of 
Lipidil-Micro™ containing micrononized fenofibrate material, while 
the second was a 145 mg of nanonized Lipidil-EZ™ tablet. This study 
was performed by comparing plasma concentration level profiles of FA 
from 41 healthy volunteers.
Materials and Methods
Chemicals and reagents
Fenofibric acid was obtained from Eskay Industries (Pune, India). 
4’-chloro-5-fluro-2-hydroxybenzophenone, phosphoric acid (85%), 
hydrochloric acid (37%) and ethyl acetate were supplied by Sigma 
Chemicals Ltd., (Poole, Dorset, UK). Acetonitrile, methanol and 
water were HPLC grade and obtained from Hichrom Ltd., (Reading, 
Berkshire, UK). The control human drug-free plasma was purchased 
from Charter House Clinical Research Unit, (London, UK).
Instrumentation
The LC system consisted of a Model 1100 series liquid 
chromatography equipped with a quadratic pump, vacuum degasser, 
thermostatic column compartment, auto-sampler and a UV detector; 
all purchased from Hewlett-Packard (Stockport, Cheshire, UK). The 
separation of fenofibric acid and CFHB (IS) was carried out using 
a mobile phase consisting of a mixture of acetonitrile and 0.02 M 
phosphoric acid (50:50, v/v) on a Symmetry Shield™ RP18 (150×4.60 
mm) 5 µm column obtained from (Waters UK Ltd., Hertfordshire, 
UK) kept at ambient temperature. Before use, the mobile phase was 
degassed for 15 min in an ultrasonic bath. The flow rate was 1 mL/min 
and UV detection was carried out at 287 nm. All data obtained were 
processed and stored on a Vectra XA computer from Hewlett-Packard 
using the HP Chemstation (Rev.A.04.02 HP-1990-1996) software.
Preparation of stock and standard solutions
Stock solutions of FA and IS were prepared by dissolving appropriate 
amounts of the compounds in methanol to give final concentrations of 
10 mg/mL and 1 mg/mL respectively. These were stored at 2-8°C, prior 
to use. Further dilutions of these stocks were made with methanol to 
give working solutions of 10 µg/mL for IS and 1 mg/mL and 10 µg/mL 
for FA. These working solutions were used to spike plasma samples 
either for a calibration curve (0.05 - 10 µg/mL) or for quality control 
during the validation. Calibration samples were prepared by spiking 
475 µL of control human plasma with the appropriate amount of 
analytes (25 µL FA and 125 µL IS) on the day of analysis. Samples for 
determination of recovery, precision and accuracy were prepared by 
spiking control plasma in bulk at appropriate concentration [0.05 µg/
mL (QC-lowest), 0.12 µg/mL (QC low), 1.20 µg/mL (QC medium) and 
8.20 µg/mL (QC high)]. These solutions were prepared and stored at 
-20°C, until analysis.
Sample preparation procedure
To 500 µL plasma sample, 125 µL of IS solution was added and 
mixed for 30 seconds with a vortex mixer. After the addition of 3 mL 
ethyl acetate and 1 mL of 1 M HCl, the mixture was vortexed for 5 
min, followed by centrifugation for 5 min at 5,500×g. The top organic 
layer was separated and evaporated to dryness at 40°C using a stream of 
nitrogen. The residue was reconstituted in 100 µL of mobile phase and 
25 µL was injected into the HPLC system.
Specificity and selectivity
The interference of endogenous fluid in plasma was investigated 
by analysing between three and six independent blank plasma samples 
and plasma spiked at the lower limit of quantitation (LLOQ).
Calibration curve
A calibration curve was acquired by plotting the peak area ratio 
of analytes FA:IS against the nominal concentration of calibration 
standards. The concentrations used were 0.05, 0.15, 0.30, 0.65, 1.25, 
2.50, 5.00 and 10.00 µg/mL FA. The calibration needed to have a 
correlation coefficient (r2) of 0.98 or better in order to be acceptable, 
according to US Food and Drugs Administration Guidelines (FDA). 
The acceptance criterion for the standards was within ± 15% deviation 
from a nominal value, except at LLOQ, which was set at ± 20%.
Precision and accuracy
The inter-and intra- assay precision and accuracy were estimated 
by analysing six replicates containing FA at four levels QC, i.e., 0.05, 
0.12, 1.20 and 8.20 µg/mL. The criterion for acceptability of the data 
was accuracy within ± 15% deviation from nominal value, except at 
LLOQ, which was set at ± 20%. A typical chromatogram of FA and 
CFHB in extracted human plasma is shown in Figure 2.
Recovery
The absolute recovery of FA and IS, through the liquid/liquid 
extraction procedure was determined by comparing the responses of 
analytes extracted from the six replicate QC samples at each level with 
the un-extracted samples. The recovery of the IS was determined at a 
single concentration.
Stability experiment
The stability of FA and IS in the biomatrix over 48 h was determined 
at ambient temperatures for four concentrations. The results obtained 
from the initial measurement were used as a reference to determine the 
relative stability of the analytes at subsequent points. Freeze stability of 
FA and IS in human plasma was assessed by analyzing the QC samples 
stored at -20°C. The stability of FA in human plasma following repeated 
freeze/thaw cycles was assessed using QC sample spiked with FA. The 
samples were stored at -20°C between freeze/thaw cycles. Samples 
were considered to be stable if %SD and precision (% RSD) is ± 15% of 
nominal value of QC’s, except for LLOQ, where it should be no more 
than 20% of the nominal value. 
Pharmacokinetics study
The method developed was used to investigate the plasma profile 
after two oral doses of FBT: a Lipidil-Micro™ 200 mg of micronised 
fenofibrate capsule as a reference and a Lipidil-EZ™ 145 mg nanonised 
fenofibrate tablet (Solvey Pharmaceuticals, Brussels, Belgium). A 
bioequivalence study on 41 healthy young male volunteers was 
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conducted. The subjects received one capsule containing 145 mg of 
Lipidil-EZ™ and blood samples were collected during 72 h. The plasma 
concentrations of FA were determined for both formulations.
Results and Discussion
Method development, specificity and selectivity
Various combinations of mobile phases were tried in order to 
get the best peak resolution and sensitivity for the analyte. The best 
resolution was achieved using 0.02 M phosphoric acid: acetonitrile 
(50:50, v/v) at 1 mL/min flow rate. The selectivity of the analytical 
method was investigated in order to prove that the method could be 
used for quantitative analysis of FA. Potential interfering substances in 
a biological matrix include endogenous fluid and metabolites of FBT. 
The selectivity was studied by analysing four individual blank plasma 
samples from different volunteers. No endogenous interference was 
observed at the analyte retention time.
Calibration curve
The calibration curve was constructed using eight calibrators with 
range of 0.05-10 µg/mL. The standard curve had a reliable reproducibility 
over the standard concentrations for FA across the calibration range. 
A calibration curve was prepared by determining the best fit peak area 
ratio (peak area analyte/peak area IS) versus concentration using a 
quadratic curve fit y=ax2+b. The average regression coefficient (r²) was 
0.9988.
Accuracy and precision
The intra and inter day precision and accuracy are given in Table 1 
along with lower limit of detection and linear range.
Recovery
Un-extracted and extracted quantity controls were measured at 
0.12, 1.2 and 8.2 µg/mL by injecting six replicates at each level. The 
absolute mean recovery was 79.8% for FA.
Stability
Over a 48 h period, mean accuracy of FA at QC 0.12, 1.2 and 8.2 
µg/mL was 83.9%, 101.8% and 103.8% and mean precision was 12.7%, 
5.5% and 6.3%, respectively.
Applications
The method was applied to the plasma samples provided by 41 
healthy, young, male volunteers who took part in a bioequivalence 
study. An ethics committee approved the protocol and the volunteers 
provided informed written consent to participate. The bioequivalence 
study was conducted according to the principles of the Declaration 
of Helsinki [27]. The study demonstrated bioequivalence between a 
micronised fenofibrate (original 200 mg capsule formulation of Lipidil-
Micro™) and a new formulation of 145 mg Lipidil-EZ™ tablets. 
Bioequivalence was assessed by measuring plasma concentrations of 
FA. Plots of the plasma FA levels (µg/mL) versus post-dose sampling 
time (h) for the micronized and the nanonized formulations are 
presented in Figure 3. Pharmacokinetic parameters (AUC0→72, AUC0→∞, 
Cmax, tmax) calculated from these data are presented in Table 2 and 
clearly demonstrate the bioequivalence of the Lipidil-EZ™ and the 
micronized formulation Lipidil-Micro™. Results were obtained from 
each sample in duplicate and the mean calculated. The concentration 
profiles of the tested drug and reference drug were similar.
These pharmacokinetic studies in healthy volunteers have 
demonstrated that a dose of 145 mg of the new nanonized Lipidil-EZ™ 
tablet is sufficient to give plasma levels equivalent to those previously 
achieved by a dose of 200 mg of the micronised fenofibrate Lipidil-
Micro™ capsule.
Conclusion
A simple, precise, accurate, economical and robust method was 
developed and validated to determine fenofibric acid in human 
plasma using a novel internal standard (4’-chloro-5-fluro-2-
hydroxybenzophenone) to meet the requirements for a pharmacokinetic 
investigation of this compound. Moreover, the sensitivity of this 
method is higher, since the determined LLOQ is 0.05 µg/mL compared 
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Figure 2: Chromatographic profile of FA (10 µg/mL) and CFHB (2.5 µg/mL) in 
extracted human plasma.
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Figure 3: Plasma concentration–time profiles of FA following a single oral dose 
of 145 mg fenofibrate. Lipidil-EZ™ and 200 mg  Lipidil-Micro™ formulation. The 
error bars represent standard error of mean.
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to previously reported methods [21-25]. This method gives narrow 
peaks, satisfactory selectivity and a short run-time as compared to 
the published methods. FA and CFHB were extracted using a single 
step liquid/liquid extraction, thus reducing cost, time and effort. The 
developed method has been successfully applied to the determination 
of FA in plasma levels for investigating the bioequivalence of a new oral 
formulation of FBT (Lipidil-EZ™ by Solvey Pharmaceuticals).
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